Who are Gadoterate meglumine (Dotarem)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gadobutrol (Gadovist/Gadavist).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gadoterate-meglumine-dotarem.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Gadoterate meglumine (Dotarem) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gadoterate meglumine (Dotarem) (Gadoterate meglumine (Dotarem)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent (GBCA). Area: Diagnostic Imaging.

phase 3 Gadolinium-based contrast agent (GBCA) Water proton relaxation (non-receptor mediated) Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Gadoterate meglumine (Dotarem) (Gadoterate meglumine (Dotarem)) — Guerbet. Gadoterate meglumine is a gadolinium-based contrast agent that enhances magnetic resonance imaging (MRI) by shortening the relaxation time of water protons in tissues.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadoterate meglumine (Dotarem) TARGET	Gadoterate meglumine (Dotarem)	Guerbet	phase 3	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (non-receptor mediated)
Gadobutrol (Gadovist/Gadavist)	Gadobutrol (Gadovist/Gadavist)	Insel Gruppe AG, University Hospital Bern	marketed	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent (GBCA) class)

Guerbet · 1 drug in this class
Insel Gruppe AG, University Hospital Bern · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gadoterate meglumine (Dotarem) — Competitive Intelligence Brief. https://druglandscape.com/ci/gadoterate-meglumine-dotarem. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab